Semaglutide boosts kidney outcomes with obesity + cardiovascular disease
May 28, 2024
At the prespecified 104-week time point, semaglutide was associated with a lesser decline in eGFR than placebo.
Statins reduce CVD risk in adults aged 75 to 85 and 85 years and older
May 28, 2024
A risk reduction was seen for overall cardiovascular disease incidence for initiating statin therapy in both intention-to-treat and per-protocol analyses.